Point72 Asset Management
ICPT

Point72 Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Point72 Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-166,300
Closed -$2.06M – 2606
2022
Q4 		$2.06M Sell
166,300
-1,392,883
-89% -$19.7M 0.01% 929
2022
Q3 		$21.8M Buy
1,559,183
+1,431,883
+1,125% +$23.1M 0.09% 305
2022
Q2 		$1.76M Buy
127,300
+50,800
+66% +$813K 0.01% 964
2022
Q1 		$1.25M Sell
76,500
-437,700
-85% -$6.86M ﹤0.01% 932
2021
Q4 		$8.38M Sell
514,200
-184,500
-26% -$3.11M 0.03% 554
2021
Q3 		$10.4M Buy
+698,700
New +$11.2M 0.05% 479
2019
Q2 		– Sell
-648,278
Closed -$72.5M – 1603
2019
Q1 		$72.5M Buy
648,278
+568,078
+708% +$62.1M 0.33% 75
2018
Q4 		$8.08M Buy
+80,200
New +$8.31M 0.04% 447
2018
Q2 		– Sell
-281,900
Closed -$17.3M – 1233
2018
Q1 		$17.3M Buy
281,900
+254,400
+925% +$15.3M 0.07% 318
2017
Q4 		$1.61M Sell
27,500
-30,000
-52% -$1.89M 0.01% 763
2017
Q3 		$3.34M Sell
57,500
-228,100
-80% -$24.6M 0.01% 606
2017
Q2 		$34.6M Buy
285,600
+65,000
+29% +$7.53M 0.19% 145
2017
Q1 		$24.9M Buy
220,600
+25,500
+13% +$2.98M 0.14% 204
2016
Q4 		$21.2M Buy
+195,100
New +$23.2M 0.15% 179
2016
Q2 		– Sell
-10,300
Closed -$1.32M – 911
2016
Q1 		$1.32M Buy
+10,300
New +$1.22M 0.01% 595
2015
Q2 		– Sell
-132,300
Closed -$37.3M – 886
2015
Q1 		$37.3M Sell
132,300
-167,900
-56% -$36.4M 0.25% 113
2014
Q4 		$46.8M Buy
300,200
+262,900
+705% +$48.6M 0.33% 93
2014
Q3 		$8.83M Buy
37,300
+10,800
+41% +$2.75M 0.07% 304
2014
Q2 		$6.27M Buy
+26,500
New +$6.98M 0.04% 417

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Point72 Asset Management's ICPT Position: Q1 2023 in Review

Point72 Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2023, closing a stake of 166,300 shares — an estimated $2.06M sold.

Point72 Asset Management first reported a position in ICPT in Q2 2014 and held it in 19 quarters. The position peaked at $72.5M in Q1 2019. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.

  • Point72 Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Point72 Asset Management sold 166,300 Intercept Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.06M.
  • Point72 Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2014 and held it in 19 quarters.
  • Point72 Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $72.5M in Q1 2019.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.

Based on Point72 Asset Management's 13F filing for Q1 2023, filed 15 May 2023.